secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001193125-22-276377
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera Q3 2022 net loss $43M, cash $596M; board adds Sandor as Nicholson resigns
--------------------------------------------------------------------------------

- Q3 2022 net loss $43.0M ($0.81/sh) vs $28.6M in Q3 2021; collaboration revenue $9.6M vs $20.3M.
- Cash, equivalents & investments $595.6M as of Sep 30, 2022; includes $150M Aug 2022 private placement.
- KT-474 (IRAK4 degrader) patient cohort dosing complete; data to Sanofi in Q4, clinical update Dec 14, 2022.
- Director Don Nicholson resigned Nov 3, 2022 (no disagreement); Victor Sandor appointed to Board same day.
- KT-333 (STAT3 degrader) granted second orphan drug designation (CTCL); KT-253 IND on track for Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312522276377/0001193125-22-276377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312522276377/d402248d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-276377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer